Poly(ADP-ribose) Polymerase Inhibitors
- Name
- Poly(ADP-ribose) Polymerase Inhibitors
- Accession Number
- DBCAT001523
- Description
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
- Drugs
Drug Drug Description Olaparib A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. Niraparib A poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy. Rucaparib A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat recurrent ovarian and prostate cancers in previously treated adults. 3-Methoxybenzamide Not Available 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide Not Available Veliparib Not Available Talazoparib A poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer and HRR gene-mutated metastatic castration-resistant prostate cancer. Iniparib Not Annotated Pamiparib Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly... Letermovir An antiviral medication used for prophylaxis in adult transplant recipients at risk of cytomegalovirus (CMV) infection and disease. Fluzoparib Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients). - Drugs & Drug Targets